AMIVANTAMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 21:18:52 GMT 2025` Edited by `admin` on `Tue Apr 01 21:18:52 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	0JSR7Z0NB6
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

AMIVANTAMAB

Official Name

English

JNJ-61186372

Preferred Name

English

IMMUNOGLOBULIN G1 (413-LYSINE), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR) (HUMAN MONOCLONAL JNJ-61186372 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL JNJ-61186372 .KAPPA.-CHAIN, (234->228'),(237->231')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (411-A

Common Name

English

Amivantamab [WHO-DD]

Common Name

English

CNTO-4424

Code

English

AMIVANTAMAB [JAN]

Common Name

English

amivantamab [INN]

Common Name

English

ANTI-EGFR/C-MET BISPECIFIC ANTIBODY JNJ-61186372

Common Name

English

JNJ-611

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1454

Created by admin on Tue Apr 01 21:18:52 GMT 2025 , Edited by admin on Tue Apr 01 21:18:52 GMT 2025

Code System Code Type Description

FDA UNII

0JSR7Z0NB6

Created by admin on Tue Apr 01 21:18:52 GMT 2025 , Edited by admin on Tue Apr 01 21:18:52 GMT 2025

PRIMARY

NCI_THESAURUS

C124993

Created by admin on Tue Apr 01 21:18:52 GMT 2025 , Edited by admin on Tue Apr 01 21:18:52 GMT 2025

PRIMARY

SMS_ID

100000177630

Created by admin on Tue Apr 01 21:18:52 GMT 2025 , Edited by admin on Tue Apr 01 21:18:52 GMT 2025

PRIMARY

WIKIPEDIA

Amivantamab

Created by admin on Tue Apr 01 21:18:52 GMT 2025 , Edited by admin on Tue Apr 01 21:18:52 GMT 2025

PRIMARY

RXCUI

2549199

Created by admin on Tue Apr 01 21:18:52 GMT 2025 , Edited by admin on Tue Apr 01 21:18:52 GMT 2025

PRIMARY

DAILYMED

0JSR7Z0NB6

Created by admin on Tue Apr 01 21:18:52 GMT 2025 , Edited by admin on Tue Apr 01 21:18:52 GMT 2025

PRIMARY

INN

11030

Created by admin on Tue Apr 01 21:18:52 GMT 2025 , Edited by admin on Tue Apr 01 21:18:52 GMT 2025

PRIMARY

CAS

2171511-58-1

Created by admin on Tue Apr 01 21:18:52 GMT 2025 , Edited by admin on Tue Apr 01 21:18:52 GMT 2025

PRIMARY

From	To
1_22	1_96
1_152	1_208
1_228	3_214
1_234	2_228
1_237	2_231
1_269	1_329
1_375	1_433
2_22	2_96
2_146	2_202
2_222	4_214
2_263	2_323
2_369	2_427
3_23	3_88
3_134	3_194
4_23	4_88
4_134	4_194

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_305
N	2_299

Related Record Type Details


					QA085PMU8Q

HEPATOCYTE GROWTH FACTOR RECEPTOR

TARGET -> INHIBITOR

Interaction Type:

BINDING

Qualification:

Kd

Amount:


					RO03J093CP

EPIDERMAL GROWTH FACTOR RECEPTOR

TARGET -> INHIBITOR

Interaction Type:

BINDING

Qualification:

Kd

Amount:


					3FJ2AHL47Q

EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTIONS

INHIBITOR -> TARGET

Comments:

Approved for treatment of EGFR EXON 20 insertions mutations in NSLC

Amount:

AMIVANTAMAB-VMJW

SUB_CONCEPT->SUBSTANCE

Amount:

Related Record Type Details


					0JSR7Z0NB6

ACTIVE MOIETY

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL